Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ZEPP · NYSE · United States · Electronic Computers
In shortZepp Health Corp is loss-making, generates cash and holds more cash than debt, with revenue shrinking (−39.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -8.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -8.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -8.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -5.8% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.04× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.34× | 92/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -4.34× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.19 | 54/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 11.5% | 66/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 39.9% | 0/100 |
| Operating margin volatility | 8.4% | 33/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -27.1% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2023 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
CNY millions; negative values in parentheses.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|
| Revenue | 5,812 | 6,433 | 6,250 | 4,143 | 2,495 |
| Cost of revenue | 4,345 | 5,101 | 4,944 | 3,340 | 1,838 |
| Gross profit | 1,468 | 1,333 | 1,306 | 803 | 658 |
| Research & development | 431 | 538 | 515 | 517 | 362 |
| Operating income | 606 | 174 | 94 | (410) | (207) |
| Interest expense | – | 23 | 45 | 57 | 48 |
| Pre-tax income | 652 | 266 | 107 | (373) | (237) |
| Income tax | 78 | 31 | 11 | (66) | (16) |
| Net income | 575 | 229 | 138 | (288) | (212) |
| Diluted EPS | ¥2.24 | ¥0.88 | ¥0.52 | −¥0.18 | −¥0.13 |
| Diluted shares (millions) | 256 | 260 | 264 | 246 | 243 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
3.19 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 24, 2026